Design of Major Randomized Trials Part 3 of a 4-Part Series on Statistics for Clinical Trials

Journal of the American College of Cardiology

Volumn 66, Issue 24, 2015, Pages 2757-2766

  Pocock, Stuart J ^a   Clayton, Tim C ^a   Stone, Gregg W ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

avoidance of bias; randomized controlled trial; sample size; selection of patients; study design; treatments and endpoints

Indexed keywords

CARDIOVASCULAR DISEASES; HUMAN; PATIENT SELECTION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS; STATISTICS AND NUMERICAL DATA;

CARDIOVASCULAR DISEASES; DATA INTERPRETATION, STATISTICAL; HUMANS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84955500088     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.10.036     Document Type: Review

References (54)

1. A.K. Jacobs, J.L. Anderson, and J.L. Halperin The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 64 2014 1373 1384
2. A.W. Chan, J.M. Tetzlaff, D.G. Altman, and et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials Ann Int Med 158 2013 200 207
3. A.W. Chan, J.M. Tetzlaff, P.C. Gøzsche, and et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials BMJ 346 2013 e7586
4. L. Wallentin, R.C. Becker, A. Budaj, and et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
5. G.W. Stone, B. Witzenbichler, G. Guagliumi, et al. for the HORIZONS-AMI Trial Investigators Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2008 2218 2230
6. G.W. Stone, B.T. McLaurin, D.A. Cox, et al. for the ACUITY Investigators Bivalirudin for patients with acute coronary syndromes N Engl J Med 355 2006 2203 2216
7. M.A. Pfeffer, K. Swedberg, C.B. Granger, et al. for the CHARM Investigators and Committees Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme [Erratum in Lancet 2009;374:1744] Lancet 362 2003 759 766
8. S. Yusuf, M.A. Pfeffer, K. Swedberg, et al. for the CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial Lancet 362 2003 777 781
9. B. Pitt, F. Zannad, W.J. Remme, et al. for the Randomized Aldactone Evaluation Study Investigators The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 1999 709 717
10. B.M. Scirica, D.L. Bhatt, E. Braunwald, et al. for the SAVOR-TIMI 53 Steering Committee and Investigators Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 369 2013 1317 1326
11. T. Svilaas, P.J. Vlaar, I.C. van der Horst, and et al. Thrombus aspiration during primary percutaneous coronary intervention N Engl J Med 358 2008 557 567
12. A. Shahzad, I. Kemp, C. Mars, et al. for the HEAT-PPCI Trial Investigators Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial [Erratum in Lancet 2014;384:1848] Lancet 384 2014 1849 1858
13. M.A. Pfeffer, B.P. Claggett, S.F. Assmann, and et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial Circulation 131 2015 34 42
14. S. Pocock, G. Calvo, J. Marrugat, and et al. International differences in treatment effect: do they really exist and why? Eur Heart J 34 2013 1846 1852
15. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, et al. for the RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
16. M.P. Bonaca, D.L. Bhatt, M. Cohen, et al. for the PEGASUS-TIMI 54 Steering Committee and Investigators Long-term use of ticagrelor in patients with prior myocardial infarction N Engl J Med 372 2015 1791 1800
17. ICH Harmonized Tripartite Guideline: Choice of Control Group and Related Issues in Clinical Trials E10 2000 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Geneva, Switzerland
18. K. Swedberg, M. Komajda, M. Böhm, et al. for the SHIFT Investigators Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study Lancet 376 2010 875 885
19. X. Rossello, S.J. Pocock, and D.G. Julian Long-term use of cardiovascular drugs: challenges for research and for patient care J Am Coll Cardiol 66 2015 1273 1285
20. J.J.V. McMurray, M. Packer, A.S. Desai, and et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure N Engl J Med 371 2014 993 1004
21. M.A. Pfeffer, J.J.V. McMurray, E.J. Velazquez, et al. for the Valsartan in Acute Myocardial Infarction Trial Investigators Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both [Erratum in N Engl J Med 2004;350:203] N Engl J Med 349 2003 1893 1906
22. B.M. Psaty, N.S. Weiss, C.D. Furberg, and et al. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease JAMA 282 1999 786 790
23. W.S. Weintraub, T.F. Lüscher, and S. Pocock The perils of surrogate endpoints Eur Heart J 36 2015 2212 2218
24. S.J. Pocock, A.J. Lansky, R. Mehran, and et al. Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials J Am Coll Cardiol 51 2008 23 32
25. C.B. Granger, V. Vogel, S.R. Cummings, and et al. Do we need to adjudicate major clinical events? Clinical Trials 5 2008 56 60
26. G. Gómez, M. Gómez-Mateu, and U. Dafni Informed choice of composite end points in cardiovascular trials Circ Cardiovasc Qual Outcomes 7 2014 170 178
27. C.R. Smith, M.B. Leon, M.J. Mack, et al. for the PARTNER Trial Investigators Transcatheter versus surgical aortic-valve replacement in high-risk patients N Engl J Med 364 2011 2187 2198
28. J.K. Rogers, S.J. Pocock, J.J.V. McMurray, and et al. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved Eur J Heart Fail 16 2014 33 40
29. Novartis Pharmaceuticals. Efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients with preserved ejection fraction (PARAGON-HF). 2015. Available at: https://clinicaltrials.gov/ct2/show/NCT01920711. Accessed October 26, 2015.
30. J.K. Rogers, P.S. Jhund, A.C. Perez, and et al. Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure) J Am Coll Cardiol HF 2 2014 289 297
31. M. Buyse Generalized pairwise comparisons of prioritized outcomes in the two-sample problem Stat Med 29 2010 3245 3257
32. D.M. Finkelstein, and D.A. Schoenfeld Combining mortality and longitudinal measures in clinical trials Stat Med 18 1999 1341 1354
33. S.J. Pocock, C.A. Ariti, T.J. Collier, and et al. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities Eur Heart J 33 2012 176 182
34. M. Packer Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure J Card Fail 7 2001 176 182
35. F. Feres, R.A. Costa, A. Abizaid, et al. for the OPTIMIZE Trial Investigators Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial JAMA 310 2013 2510 2522
36. J.B. Schroll, E. Maund, and P.C. Gøtzsche Challenges in coding adverse events in clinical trials: a systematic review PLoS One 7 2012 e41174
37. Y. Hochberg A sharper Bonferroni procedure for multiple tests of significance Biometrika 75 1988 800 802
38. S.J. Pocock, and D.R. Elbourne Randomized trials or observational tribulations? N Engl J Med 342 2000 1907 1909
39. M.L. Brown, B.J. Gersh, D.R. Holmes, and et al. From randomized trials to registry studies: translating data into clinical information Nat Clin Pract Cardiovasc Med 5 2008 613 620
40. K.F. Schulz, and D.A. Grimes Generation of allocation sequences in randomised trials: chance, not choice Lancet 359 2002 515 519
41. D. Moher, S. Hopewell, K.F. Schulz, and et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials BMJ 340 2010 c869
42. M. Valgimigli, A. Gagnor, P. Calabró, et al. for the MATRIX Investigators Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial Lancet 385 2015 2465 2476
43. CURRENT-OASIS 7 Investigators Dose comparisons of clopidogrel and aspirin in acute coronary syndromes N Engl J Med 363 2010 930 942
44. T. Treasure, and K.D. MacRae Minimisation: the platinum standard for trials? Randomisation doesn't guarantee similarity of groups; minimisation does BMJ 317 1998 362 363
45. G.J. Murphy, K. Pike, C.A. Rogers, et al. for the TITRe2 Investigators Liberal or restrictive transfusion after cardiac surgery N Engl J Med 372 2015 997 1008
46. J.C. Dumville, S. Hahn, J.N.V. Miles, and D.J. Torgerson The use of unequal randomisation ratios in clinical trials: a review Contemp Clin Trials 27 2006 1 12
47. D.L. Bhatt, D.E. Kandzari, W.W. O'Neill, and et al. A controlled trial of renal denervation for resistant hypertension N Engl J Med 370 2014 1393 1401
48. K.F. Schulz, and D.A. Grimes Blinding in randomised trials: hiding who got what Lancet 359 2002 696 700
49. B.M. Psaty, and R.L. Prentice Minimizing bias in randomized trials: the importance of blinding JAMA 304 2010 793 794
50. C.B. Granger, J.H. Alexander, J.J.V. McMurray, et al. for the ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
51. E.M. Antman Evidence and education Circulation 123 2011 681 685
52. R. Gulati, C.E. Raphael, M. Negoita, and et al. The rise and fall and possible resurrection of renal denervation Nat Rev Cardiol 2015 In press
53. J. Wittes Sample size calculations for randomized controlled trials Epidemiol Rev 24 2002 39 53
54. D.L. Bhatt, G.W. Stone, K.W. Mahaffey, et al. for the CHAMPION PHOENIX Investigators Effect of platelet inhibition with cangrelor during PCI on ischemic events N Engl J Med 368 2013 1303 1313